Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS); human isolates final report, 2010
  • Published Date:
Filetype[PDF-38.79 MB]

This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS); human isolates final report, 2010
  • Alternative Title:
    Human isolates final report, 2010 ; NARMS ;
  • Description:
    List of tables -- List of figures -- List of boxes -- List of abbreviations and acronyms -- NARMS Working Group -- Introduction -- What is new in the NARMS report for 2010 -- Summary of NARMS 2010 surveillance data -- Antimicrobial resistance: 1996-2010 -- WHO categorization of antimicrobial agents -- Surveillance and laboratory testing methods - Results -- Appendix A. Summary of non-typhoidal salmonella strains that caused outbreaks, United States, 2004-2008 -- Appendix B. Criteria for retesting of isolates.

    The primary purpose of the National Antimicrobial Resistance Monitoring System (NARMS) at CDC is to monitor antimicrobial resistance among enteric bacteria isolated from humans. Other components of the interagency NARMS program include surveillance for resistance in enteric bacteria isolated from foods, conducted by the FDA-CVM (http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/default.htm), and resistance in enteric bacteria isolated from animals, conducted by the USDA Agricultural Research Service (http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08). Many NARMS activities are conducted within the framework of CDC's Emerging Infections Program (EIP), Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network (FoodNet). In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also includes research into the mechanisms and public health impact of resistance, education efforts to promote prudent use of antimicrobial agents, and antimicrobial susceptibility testing of isolates that caused outbreaks. Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella and Escherichia coli O157 isolates in 14 sites. In 1997, testing of clinical Campylobacter isolates was initiated in the five sites participating in FoodNet. Testing of clinical Salmonella enterica serotype Typhi and Shigella isolates was added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, Salmonella ser. Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states have been participating in Campylobacter surveillance. Since 2008, all 50 states have been forwarding every Salmonella Paratyphi A and C to NARMS for antimicrobial susceptibility testing. This annual report includes CDC's surveillance data for 2010 for non-typhoidal Salmonella, typhoidal Salmonella, Shigella, Campylobacter and E. coli O157 isolates in addition to surveillance data for 2009 Vibrio species other than V. cholerae. Data for earlier years are presented in tables and graphs when appropriate. Antimicrobial classes defined by Clinical and Laboratory Standards Institute (CLSI) are used in data presentation and analysis. CLSI classes constitute major classifications of antimicrobial agents, e.g., aminoglycosides and cephems. This report also includes the World Health Organization's categorization of antimicrobials of critical importance to human medicine (Table 1). The table includes only antimicrobials that are tested in NARMS.

  • Content Notes:
    C5215511-A. ; Available via the World Wide Web as an Acrobat .pdf file (2.23 MB, 75 p.). ; Includes bibliographical references (p. 66-67). ;
  • Document Type:
  • Place as Subject:
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: